Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Pfizer Inc. stock logo
PFE
Pfizer
$21.81
+1.0%
$25.33
$20.92
$31.54
$123.25B0.6740.09 million shs23.20 million shs
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$550.61
+0.8%
$662.80
$525.99
$1,211.20
$60.20B0.44980,106 shs467,763 shs
Sanofi stock logo
SNY
Sanofi
$51.38
+3.5%
$55.01
$45.22
$60.12
$129.79B0.572.67 million shs1.34 million shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Pfizer Inc. stock logo
PFE
Pfizer
-4.14%-11.22%-17.04%-19.31%-18.01%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
-5.26%-10.52%-23.92%-21.59%-41.64%
Sanofi stock logo
SNY
Sanofi
-3.03%-9.08%-15.46%+1.91%+5.37%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Pfizer Inc. stock logo
PFE
Pfizer
4.9912 of 5 stars
4.33.04.24.32.73.33.1
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
4.6915 of 5 stars
4.43.01.72.33.31.71.9
Sanofi stock logo
SNY
Sanofi
3.2091 of 5 stars
2.53.02.50.02.90.03.1
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Pfizer Inc. stock logo
PFE
Pfizer
2.59
Moderate Buy$31.0742.48% Upside
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
2.76
Moderate Buy$966.8875.60% Upside
Sanofi stock logo
SNY
Sanofi
3.00
Buy$62.5021.65% Upside

Current Analyst Ratings Breakdown

Latest REGN, PFE, and SNY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/8/2025
Pfizer Inc. stock logo
PFE
Pfizer
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$28.00 ➝ $24.00
4/8/2025
Pfizer Inc. stock logo
PFE
Pfizer
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$32.00 ➝ $25.00
3/31/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$1,100.00 ➝ $1,000.00
3/27/2025
Pfizer Inc. stock logo
PFE
Pfizer
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
3/21/2025
Sanofi stock logo
SNY
Sanofi
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$65.00
3/18/2025
Pfizer Inc. stock logo
PFE
Pfizer
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
3/12/2025
Pfizer Inc. stock logo
PFE
Pfizer
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
3/10/2025
Pfizer Inc. stock logo
PFE
Pfizer
Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
2/10/2025
Pfizer Inc. stock logo
PFE
Pfizer
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$33.00 ➝ $33.00
2/5/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
2/5/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$940.00 ➝ $759.00
(Data available from 4/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Pfizer Inc. stock logo
PFE
Pfizer
$63.63B1.94$3.42 per share6.38$15.81 per share1.38
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$14.20B4.24$36.15 per share15.23$268.50 per share2.05
Sanofi stock logo
SNY
Sanofi
$44.29B2.93$5.06 per share10.16$33.20 per share1.55
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Pfizer Inc. stock logo
PFE
Pfizer
$8.03B$1.4115.417.200.6412.62%19.47%8.09%4/29/2025 (Estimated)
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$4.41B$38.2814.3814.482.3431.07%16.32%12.76%4/29/2025 (Estimated)
Sanofi stock logo
SNY
Sanofi
$6.02B$2.4920.6310.821.0112.77%25.61%14.72%4/24/2025 (Estimated)

Latest REGN, PFE, and SNY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/29/2025Q1 2025
Pfizer Inc. stock logo
PFE
Pfizer
$0.67N/AN/AN/A$14.43 billionN/A
4/29/2025Q1 2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$8.83N/AN/AN/A$3.40 billionN/A
4/24/2025Q1 2025
Sanofi stock logo
SNY
Sanofi
$0.87N/AN/AN/A$9.79 billionN/A
2/4/2025Q4 2024
Pfizer Inc. stock logo
PFE
Pfizer
$0.48$0.63+$0.15$0.07$17.26 billion$17.76 billion
2/4/2025Q4 2024
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$11.21$12.07+$0.86$8.06$3.76 billion$3.79 billion
1/30/2025Q4 2024
Sanofi stock logo
SNY
Sanofi
$0.70$0.70N/A$0.29$10.57 billionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Pfizer Inc. stock logo
PFE
Pfizer
$1.727.89%+2.50%121.99%16 Years
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$0.880.16%N/A2.30%N/A
Sanofi stock logo
SNY
Sanofi
$1.472.86%+1.84%59.04%N/A

Latest REGN, PFE, and SNY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/20/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
quarterly$0.880.53%2/20/20252/20/20253/20/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Pfizer Inc. stock logo
PFE
Pfizer
0.63
1.00
0.73
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
0.09
4.73
3.95
Sanofi stock logo
SNY
Sanofi
0.15
1.46
1.14

Institutional Ownership

CompanyInstitutional Ownership
Pfizer Inc. stock logo
PFE
Pfizer
68.36%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
83.31%
Sanofi stock logo
SNY
Sanofi
14.04%

Insider Ownership

CompanyInsider Ownership
Pfizer Inc. stock logo
PFE
Pfizer
0.06%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
7.48%
Sanofi stock logo
SNY
Sanofi
1.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Pfizer Inc. stock logo
PFE
Pfizer
83,0005.67 billion5.66 billionOptionable
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
11,900109.33 million101.15 millionOptionable
Sanofi stock logo
SNY
Sanofi
91,6002.53 billion2.51 billionOptionable

Recent News About These Companies

Why You Shouldn't Bet Against Sanofi (SNY) Stock
Novavax price target lowered to $10 from $12 at BofA
Sanofi stock logo
Sanofi (NASDAQ:SNY) Shares Purchased by Invesco Ltd.

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Pfizer stock logo

Pfizer NYSE:PFE

$21.81 +0.22 (+1.01%)
As of 01:07 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Regeneron Pharmaceuticals stock logo

Regeneron Pharmaceuticals NASDAQ:REGN

$550.61 +4.22 (+0.77%)
As of 01:07 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Sanofi stock logo

Sanofi NASDAQ:SNY

$51.38 +1.72 (+3.46%)
As of 01:06 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.